New drug combo shows promise for Hard-to-Treat breast cancer
Disease control
Ongoing
This study tests a drug called alpelisib combined with standard hormone therapy for people with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) whose cancer has worsened on hormone therapy alone. About 44 participants will take alpelisib daily along…
Phase: PHASE2 • Sponsor: Marina N Sharifi • Aim: Disease control
Last updated May 17, 2026 11:48 UTC